Sprint and T-Mobile, the nation’s third- and fourth-largest wireless operators, respectively, have reportedly called off their highly publicized plans to merge.
According to reports, Sprint is set to announce Wednesday that it will no longer pursue a takeover of its smaller rival. Experts suspect Sprint, owned by SoftBank, has finally accepted that regulatory hurdles are much too high.
For months news has been circulated about a possible deal valued at about $35 billion and higher, at times. But with several major media mergers in the works – including Comcast’s acquisition of Time Warner Cable – industry experts had doubted a merger of two major wireless competitors would receive antitrust approval.
The takeover would have needed approval from both the US Department of Justice and the Federal Communications Commission.
Still, the companies seemed confident in their plans. SoftBank and T-Mobile parent Deutsche Telekom had reportedly agreed to a $2 billion breakup fee should the deal be thwarted.
Now, however, Sprint seems to have accepted defeat. Late last week French wireless operator Iliad had offered $15 billion to acquire T-Mobile, a bid that may have helped propel the fall of the Sprint/T-Mobile tie-up.
News of the failed merger emerged form unnamed sources late Tuesday. One of those sources also said that Sprint is expected to announce a new CEO to replace current leader Dan Hesse, reports say.
Full content: USA Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Brazil’s Antitrust Watchdog Expected to Approve Pet Retail Merger Without Conditions
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas